Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) filed a Form 8-K on November 25, 2022, reporting the entry into a material definitive agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and trades on the NASDAQ Global Select Market.
Key Financial Metrics
This filing details a specific capital raise event rather than periodic financial performance. Key transaction metrics include:
- Gross Proceeds: Approximately $5.0 million.
- Shares Issued: 627,746 shares of common stock.
- Purchase Price: $7.97 per share.
- Transaction Date: Closed on November 25, 2022.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific offering.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital resulting from the private placement. The transaction was conducted under Section 4(a)(2) of the Securities Act of 1933, exempting it from registration requirements.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclosures. The shares issued are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption. The company granted piggyback registration rights to the purchasers and agreed to indemnify them under future registration statements.
Investor Verification Checklist
- Verify the dilution impact of the 627,746 newly issued shares on existing shareholders.
- Confirm the identity of the purchasers (entities affiliated with Wynnefield Capital, Inc.) and their existing holdings.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants, indemnification limits, and registration rights.
- Check subsequent filings to determine if the company intends to register these shares for public resale.